The Conversation (0)
Hemostemix Signs Manufacturing Agreement with Aspire Health Science
Feb. 22, 2018 09:32AM PST
Biotech InvestingHemostemix (TSXV:HEM) is pleased to announce it has finalized the terms of a contract manufacturing services agreement with Aspire Health Science, LLC underpinning the previously announced transition of the Company’s stem cell manufacturing operations from Company owned facilities in Israel to a third party operator in North America. As quoted in the press release: Angus Jenkins, …
Hemostemix (TSXV:HEM) is pleased to announce it has finalized the terms of a contract manufacturing services agreement with Aspire Health Science, LLC underpinning the previously announced transition of the Company’s stem cell manufacturing operations from Company owned facilities in Israel to a third party operator in North America.
As quoted in the press release:
Angus Jenkins, Chair of the Board of Hemostemix noted: “After careful evaluation, Aspire was clearly the best fit for our current objectives. The agreement allows Hemostemix to streamline the production of ACP-01 for our current trials, while ensuring the highest quality is maintained in a regulated and certified lab. Aspire’s lab has undergone strict testing to ensure that all the FDA requirements and clinical trial protocols can be executed with the highest quality standards.”